GuiSen Wu1, RanPiao Gan1, ZhiXing Li1, LiHua Xu1, XiaoChen Tang1, YanYan Wei1, YeGang Hu1, HuiRu Cui1, HuiJun Li2, YingYing Tang1, Li Hui3, XiaoHua Liu1, ChunBo Li1, JiJun Wang1,4,5, TianHong Zhang1. 1. Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, People's Republic of China. 2. Florida a & M University, Department of Psychology, Tallahassee, FL 32307, USA. 3. Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, Soochow University, Suzhou 215137, Jiangsu, People's Republic of China. 4. Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai, People's Republic of China. 5. Brain Science and Technology Research Center, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Abstract
BACKGROUND: The clinical high-risk (CHR) state is identified as a critical period for early prevention and intervention during the development of psychosis and early treatment may reduce the risk of conversion to psychosis. However, it remains controversial whether antipsychotics are effective in CHR populations. Limited previous randomised controlled trials of antipsychotic treatment of CHR individuals indicated possible short-term efficacy on psychotic symptoms with unclear long-term effects. To answer this question, it is necessary to establish a high-quality real-world cohort study with large sample size to explore the effectiveness and safety of antipsychotics in CHR individuals. METHODS: We plan to consecutively recruit 600 CHR individuals from Shanghai Mental Health Centre in the ongoing SHARP-2 (ShangHai At Risk for Psychosis-Phase 2) project between 2019 and 2022. At baseline, participants will be assessed by the Structured Interview for Prodromal Syndromes, the MATRICS Consensus Cognitive Battery, demographic information, and clinical medication history. They will be followed up in a naturalistic way in which the research team will not prescribe antipsychotics or provide pharmacological consultation. First, CHR participants and their families will be trained to record their medication daily and self-evaluate symptoms through smart-phone application-based assessment and report their information weekly. Second, telephone calls will be arranged monthly so that the researchers are informed about the participants' symptoms, medications and daily functions. Third, face-to-face interviews will be conducted annually for repeating assessment of baseline. The primary outcomes will include conversion to psychosis and functional outcome (scored with less than 60 in the Global Assessment of Function) at the end of the follow-up period. CONCLUSION: The current study will improve our knowledge on the effectiveness and safety of the use of antipsychotics at the prodromal phase, and will eventually facilitate optimisation of individualised interventions for psychosis prevention and treatment.
BACKGROUND: The clinical high-risk (CHR) state is identified as a critical period for early prevention and intervention during the development of psychosis and early treatment may reduce the risk of conversion to psychosis. However, it remains controversial whether antipsychotics are effective in CHR populations. Limited previous randomised controlled trials of antipsychotic treatment of CHR individuals indicated possible short-term efficacy on psychotic symptoms with unclear long-term effects. To answer this question, it is necessary to establish a high-quality real-world cohort study with large sample size to explore the effectiveness and safety of antipsychotics in CHR individuals. METHODS: We plan to consecutively recruit 600 CHR individuals from Shanghai Mental Health Centre in the ongoing SHARP-2 (ShangHai At Risk for Psychosis-Phase 2) project between 2019 and 2022. At baseline, participants will be assessed by the Structured Interview for Prodromal Syndromes, the MATRICS Consensus Cognitive Battery, demographic information, and clinical medication history. They will be followed up in a naturalistic way in which the research team will not prescribe antipsychotics or provide pharmacological consultation. First, CHR participants and their families will be trained to record their medication daily and self-evaluate symptoms through smart-phone application-based assessment and report their information weekly. Second, telephone calls will be arranged monthly so that the researchers are informed about the participants' symptoms, medications and daily functions. Third, face-to-face interviews will be conducted annually for repeating assessment of baseline. The primary outcomes will include conversion to psychosis and functional outcome (scored with less than 60 in the Global Assessment of Function) at the end of the follow-up period. CONCLUSION: The current study will improve our knowledge on the effectiveness and safety of the use of antipsychotics at the prodromal phase, and will eventually facilitate optimisation of individualised interventions for psychosis prevention and treatment.
Authors: A Bechdolf; M Wagner; S Ruhrmann; S Harrigan; V Putzfeld; R Pukrop; A Brockhaus-Dumke; J Berning; B Janssen; P Decker; R Bottlender; K Maurer; H-J Möller; W Gaebel; H Häfner; W Maier; J Klosterkötter Journal: Br J Psychiatry Date: 2011-11-10 Impact factor: 9.319
Authors: Tandy J Miller; Thomas H McGlashan; Joanna L Rosen; Kristen Cadenhead; Tyrone Cannon; Joseph Ventura; William McFarlane; Diana O Perkins; Godfrey D Pearlson; Scott W Woods Journal: Schizophr Bull Date: 2003 Impact factor: 9.306
Authors: Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Barnaby Nelson; Hok Pan Yuen; Stephen J Wood; Ashleigh Lin; Daniela Spiliotacopoulos; Annie Bruxner; Christina Broussard; Magenta Simmons; Debra L Foley; Warrick J Brewer; Shona M Francey; G Paul Amminger; Andrew Thompson; Patrick D McGorry; Alison R Yung Journal: JAMA Psychiatry Date: 2013-08 Impact factor: 21.596
Authors: Patrick D McGorry; Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona Francey; Elizabeth M Cosgrave; Dominic Germano; Jenny Bravin; Tony McDonald; Alison Blair; Stephen Adlard; Henry Jackson Journal: Arch Gen Psychiatry Date: 2002-10
Authors: Stephen F Austin; Ole Mors; Rikke Gry Secher; Carsten R Hjorthøj; Nikolai Albert; Mette Bertelsen; Heidi Jensen; Pia Jeppesen; Lone Petersen; Lasse Randers; Anne Thorup; Merete Nordentoft Journal: Schizophr Res Date: 2013-08-08 Impact factor: 4.939
Authors: Anthony P Morrison; Paul French; Suzanne L K Stewart; Max Birchwood; David Fowler; Andrew I Gumley; Peter B Jones; Richard P Bentall; Shôn W Lewis; Graham K Murray; Paul Patterson; Kat Brunet; Jennie Conroy; Sophie Parker; Tony Reilly; Rory Byrne; Linda M Davies; Graham Dunn Journal: BMJ Date: 2012-04-05